Literature DB >> 25320223

Hospitalized infections in giant cell arteritis: a population-based retrospective cohort study.

Prabhu D Udayakumar1, Arun K Chandran2, Cynthia S Crowson2, Kenneth J Warrington2, Eric L Matteson2.   

Abstract

OBJECTIVE: To assess the occurrence of infections requiring or acquired during hospitalization in patients with giant cell arteritis (GCA).
METHODS: We retrospectively reviewed a population-based incidence cohort of patients with GCA diagnosed between 1950 and 2009 and compared this cohort with a non-GCA one matched for age, sex, and calendar year from the same population.
RESULTS: We identified 245 patients in the GCA cohort and 245 patients in the non-GCA cohort. Seventy-four GCA subjects (134 episodes) and 79 non-GCA (153 episodes) had infections requiring or acquired during hospitalization [rate ratio (RR) 0.94; 95% CI 0.74, 1.18]. Sixty-seven subjects (107 episodes) in the GCA cohort and 63 subjects (110 episodes) in non-GCA cohort required hospitalization secondary to an infection (RR 1.04; CI 0.80, 1.36). Pneumonia, urinary tract infections (UTI), skin and soft tissue infections accounted for the majority of infections requiring hospitalization and had similar occurrence in both cohorts. UTI accounted for the majority of infections requiring hospitalization in the first 6 months after GCA incidence (RR 3.93; CI 0.85, 56.52). No difference between the 2 cohorts was noted in overall infections acquired during hospitalization (RR 0.68; CI 0.41, 1.08).
CONCLUSION: There is no overall increased risk of infections requiring or acquired during hospitalization in patients with GCA who are taking glucocorticoid therapy. There may be an increased risk of infections requiring hospitalization, especially of the urinary tract, in the first 6 months after GCA incidence, although this did not achieve statistical significance in our study.

Entities:  

Keywords:  COHORT STUDIES; GIANT CELL ARTERITIS; HOSPITALIZATION; INFECTION

Mesh:

Substances:

Year:  2014        PMID: 25320223      PMCID: PMC4254117          DOI: 10.3899/jrheum.140124

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  15 in total

1.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.

Authors:  G G Hunder; D A Bloch; B A Michel; M B Stevens; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie
Journal:  Arthritis Rheum       Date:  1990-08

Review 2.  The treatment of giant cell arteritis.

Authors:  J Alexander Fraser; Cornelia M Weyand; Nancy J Newman; Valérie Biousse
Journal:  Rev Neurol Dis       Date:  2008

Review 3.  Epidemiology of giant cell arteritis and polymyalgia rheumatica.

Authors:  Miguel A Gonzalez-Gay; Tomas R Vazquez-Rodriguez; Maria J Lopez-Diaz; Jose A Miranda-Filloy; Carlos Gonzalez-Juanatey; Javier Martin; Javier Llorca
Journal:  Arthritis Rheum       Date:  2009-10-15

4.  Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study.

Authors:  Valentin S Schäfer; Tanaz A Kermani; Cynthia S Crowson; Gene G Hunder; Sherine E Gabriel; Steven R Ytterberg; Eric L Matteson; Kenneth J Warrington
Journal:  Rheumatology (Oxford)       Date:  2010-07-13       Impact factor: 7.580

5.  Statin use in giant cell arteritis: a retrospective study.

Authors:  Jean Schmidt; Tanaz A Kermani; Francesco Muratore; Cynthia S Crowson; Eric L Matteson; Kenneth J Warrington
Journal:  J Rheumatol       Date:  2013-04-01       Impact factor: 4.666

6.  Risk of infectious complications in patients taking glucocorticosteroids.

Authors:  A E Stuck; C E Minder; F J Frey
Journal:  Rev Infect Dis       Date:  1989 Nov-Dec

7.  [Horton's disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients. Towards a reduced initial dose].

Authors:  P Chevalet; J H Barrier; J Glémarec; D el Kouri; M Hamidou; B de Wazières; E Duhamel; P Jégo; Y Maugars; B Planchon; O Rodat
Journal:  Rev Med Interne       Date:  2001-07       Impact factor: 0.728

8.  Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis.

Authors:  Miguel A Gonzalez-Gay; Angela Piñeiro; Adriana Gomez-Gigirey; Carlos Garcia-Porrua; Robustiano Pego-Reigosa; Trinidad Dierssen-Sotos; Javier Llorca
Journal:  Medicine (Baltimore)       Date:  2004-11       Impact factor: 1.889

9.  Epidemiological and clinical features of giant cell arteritis in Tunisia.

Authors:  Mabrouk Khalifa; Monia Karmani; Nairouz Ghannouchi Jaafoura; Naoufel Kaabia; Amel Omezzine Letaief; Fethi Bahri
Journal:  Eur J Intern Med       Date:  2008-09-02       Impact factor: 4.487

Review 10.  Polymyalgia rheumatica and giant-cell arteritis.

Authors:  Carlo Salvarani; Fabrizio Cantini; Gene G Hunder
Journal:  Lancet       Date:  2008-07-19       Impact factor: 79.321

View more
  1 in total

1.  Does low risk of infections as a marker of effective immunity predict increased risk of subsequent giant cell arteritis or polymyalgia rheumatica? A Danish population-based case-control study.

Authors:  Clément Brault; Anders H Riis; Anil Mor; Pierre Duhaut; Reimar W Thomsen
Journal:  Clin Epidemiol       Date:  2018-10-16       Impact factor: 4.790

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.